【文献解读】Kochia indica提取物中是否添加5-氟尿嘧啶在体外实验下对人肝癌细胞系抗肿瘤效能的比较
2017/7/29 创新医学网

     文章来源:欧尔意 OAE 微信号

     作者 :sofina

    

     原文出处

     Abdel-Hamid NM, Tabl GA, El-Bolkiny YE, Zeina WO. In vitro antitumor efficacy of Kochia indicaextract on human hepatocellular carcinoma cell line with or without 5-fluorouracil. Hepatoma Res 2017;3:149-55.

     DOI:10.20517/2394-5079.2016.50.

     摘要

     目的:肝癌是一种极常见的原发性肝脏恶性肿瘤,位于全球最常见肿瘤第六位。在肝癌治疗中,对化疗药物产生抗性是其中遇到的主要问题,因此我们需要寻找其它药物投入使用。国际上有越来越多的人都在使用抗癌补充物或是备选药物治疗疾病。因此,本研究的目的在于确定一种合适且有效的新型标记物,主要筛选方法是通过检测癌症发生和治疗中,标记物表现出的显著变化和重复性表达得以实现。方法:将HepG2 细胞系分成4组:未处理组(对照组);不同浓度(15.625, 31.2, 62.5, 125, 250 μg/mL)5-氟尿嘧啶处理组,即肝癌化疗的标准方案组(阳性对照);不同浓度(12.5, 25, 50, 100, 200 μg/mL)Kochia indica 处理组;以及不同浓度比例处理的5-氟尿嘧啶和Kochia indica 联合用药组。结果:与对照组相比,加入Kockia indica 提取物、5-氟尿嘧啶或两者共同处理HepG2 细胞,通过实验后得到的IC50,都显示出了明显的细胞毒性。5-氟尿嘧啶处理组的IC50为237.56 μg/mL,与Kochia indica 处理组的IC50值120.5μg/mL 相比,毒性更低。以上结果也说明,肿瘤细胞对5-氟尿嘧啶的耐药性更强。或者说,加入Kockia indica 提取物的联合用药组,改变了5-氟尿嘧啶引起的细胞毒性,增加了Kochia indica 的治疗潜能;不论是二者的协同作用或是其本身具有的黄酮类成分,都有可能增强细胞膜的生理学特性,使5-氟尿嘧啶更容易进入肿瘤细胞。而采用联合用药的方法,能使其治疗剂量降低到250 μg/mL 以下。结论:本次研究结果认为,Kochia indica 提取物的联合治疗可以通过增强细胞摄取,改变5-氟尿嘧啶对肝癌细胞HpG2的毒性。

     关键词:肝癌,Kochia indica, 5-氟尿嘧啶,肝癌细胞,化疗增效。

     Aim:Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the sixth most common cancer worldwide. The resistance to chemotherapy is a major obstacle in the treatment of HCC, necessitating the discovery of additional agents. There is a growing use of anticancer complementary and alternative medicine worldwide. Therefore, the aim of present study was focused on the confirmation of the suitability and validity of the new markers which would be achieved by demonstrating their significant change and reproducible expression during disease and disease management. Methods:HepG2 cell line was used to provide a source for HCC cells. The cell cultures were divided into 4 groups: control untreated group, 5-fluorouracil (5-FU) treated group as a standard chemotherapy for HCC (positive control) with the following doses (15.625, 31.2, 62.5, 125, 250 μg/mL), Kochia indica extract treated group with the following concentration (12.5, 25, 50, 100, 200 μg/mL) and the group treated with a combination of 5-FU and Kochia indica in different ratios. Results:Treatment with Kockia indica extract, 5-FU and the combined treatment showed a significant cytotoxicity to HepG2 cells, with different IC50 values, when compared to the control. Regarding toxic effect, 5-FU showed IC50 = 237.56 μg/mL which is lower cytotoxic in compared to Kochia indica with IC50 =120.5 μg/mL. The results also revealed that tumor cells were more resistant to 5-FU. Alternatively, the co-treatment with Kochia indica extract ameliorated the toxicity induced by 5-FU and enhanced its therapeutic potency, either by synergistic effect of both agents and/ or due to its flavonoid components that may enhance the physiological properties of the cell membranes, facilitating 5-FU entrance into tumor cells. This decreased its therapeutic dose to less than 250 μg/mL by combination therapy. Conclusion:Present findings assume that Kochia indica extract co-therapy can ameliorate the side effects of 5-FU on HepG2 by enhancing its cellular uptake.

     Key words:Hepatocellular carcinoma, Kochia indica, 5-fluorouracil, cells of hepatoma cell line, chemosensitization.

     原文链接

     各位读者可复制此链接在浏览器中打开。

     http://hrjournal.net/article/view/1847

     或点击屏幕左下方“阅读原文”,免费获取全文!

     联系我们

     Hepatoma Research旨在报道肝癌最新研究进展,为该领域的研究学者和临床医生提供一个国际性学术交流平台。自2015年4月创刊以来,期刊读者遍布全球156个国家和地区,已在线发表文章103篇。诚挚欢迎您向我刊投稿,如有疑问,请邮件:

     editor001@hrjournal.net。

     * 本文中文摘要翻译内容由 OAE Publishing Inc.北京办公室负责翻译。中文内容仅供参考,一切内容以英文原版为准。

     本文转载已获OAE 微信号 授权 更多精彩,点击下方“阅读原文”查看。

    http://weixin.100md.com
返回 创新医学网 返回首页 返回百拇医药